Information Provided By:
Fly News Breaks for March 1, 2019
APTO
Mar 1, 2019 | 09:07 EDT
RBC Capital analyst Gregory Renza initiated Aptose Biosciences with an Outperform and $6 price target citing the promising profile and solid per-clinical data for key asset CG-806. Renza sees an opportunity as clinical data generated to de-risk and increase appreciation for its prospects in the complex heme/onc treatment paradigm and a driver of share upside.